653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Racial and socioeconomic disparities in smoldering multiple myeloma Insights from the surveillance epidemiology and end Results SEER database

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Sensitive peripheral residual disease PRD detection using clonotypic mass spectrometry EasyM in patients with newly diagnosed multiple myeloma NDMM

Thromboembolic and cardiovascular events after CAR T cell therapy in multiple myeloma A propensity matched real world analysis

Patients with multiple myeloma and CKD Should we really hold off on bispecific therapy in this subgroup

Computational immunophenotypic profiling of multiple myeloma by flow cytometry and bioinformatics integration

Prognostic significance of 1q21 gain amplification and co existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma

Predictors of renal recovery in newly diagnosed multiple myeloma with light chain cast nephropathy

Head to head longitudinal comparison of two mass spectrometry based methods for monitoring monoclonal proteins in multiple myeloma Analytical and clinical insights from the GEM CESAR trial

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma An ASH research collaborative data hub analysis

BCMA extracellular vesicles predict response and toxicity in patients with multiple myeloma treated with anti BCMA bispecific antibodies

Measurable residual disease in newly diagnosed multiple myeloma Experience from a large cohort from an academic medical center

Lenalidomide related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

Tracking MRD in multiple myeloma Soluble BCMA reflects flow cytometry changes

Pre diagnostic biomarkers show disease susceptibility continuum and enable early prediction of multiple myeloma

Pomalidomide salvage in T cell engager monotherapy failures Real world experience with talquetamab or elranatamab with pomalidomide combinations in heavily pretreated multiple myeloma

Incidence and risk factors for infections in the real world setting in newly diagnosed myeloma patients treated with modern induction regimens

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Clinical course predictors of development and therapeutic response in multiple myeloma with central nervous system involvement

Artificial intelligence accelerates the identification of measurable residual multiple myeloma by flow cytometry

Assessment of pharmacodynamic efficacy biomarkers from A phase 1 first in human study of arlocabtagene autoleucel arlo cel in relapsed and refractory multiple myeloma RRMM

Beyond FISH CMA detects 8p xq and y as markers of early post transplant progression in myeloma

Cytogenetic testing in newly diagnosed multiple myeloma NDMM Real world evidence of adverse outcomes for high risk groups

Prospective real world evaluation of SKY92 for risk stratification in multiple myeloma Comparison with updated ims IMWG criteria in the prommis study

Pilot study of cell free DNA cfDNA for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Feasibility of risk classification with newly proposed international myeloma working group IMWG high risk definition A single center analysis using natural language processing

Novel method of minimal residual disease testing in myeloma Liquid biopsies to enumerate and 3D telomere profiling of circulating tumor cells

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression free survival

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel Phase 3 CARTITUDE 4 study of patients with relapsed lenalidomide refractory multiple myeloma

Bridging therapy response and low pre lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Real world study on discontinuation strategies after MRD negativity in multiple myeloma patients

Dexamethasone dose intensity does not improve 6 month responses in newly diagnosed multiple myeloma and may contribute to hyperglycemia

Multiple myeloma with ≥1 circulating plasma cells in peripheral blood has a poor prognosis

Correlative biomarker analyses of etentamig in patients with Relapsed Refractory multiple myeloma RRMM at optimal dose support its potential to maximize T cell activity with rapid and transient proinflammatory cytokine responses

Impact of low disease burden on the safety and efficacy of BCMA CAR T in patients with Relapsed Refractory multiple myeloma

Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma